Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36749325.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3882 and PMC identifier 10106381.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies. See related article by Klümper et al., p. 1496.
Medical subject headings
- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell